🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lenvatinib + pembrolizumab found not to have a favorable benefit‒risk profile v placebo + pembrolizumab in LEAP-007 study. Pembrolizumab monotherapy remains an approved treatment option for some first-line metastatic #NSCLC. Learn More: bit.ly/3SSiRPn #LCSM

Household particulate matter (PM) air pollution is substantially associated w/#lungcancer. However, the prevalence of lung cancer attributable to household PM2.5 has declined from 1990 to 2019 owing to a concurrent decline in household PM2.5 exposure:bit.ly/4bt4xTu #LCSM

For July Editor's Choice, explore the epidemiology, staging, screening, and management of #ungcancer in Ghana in this issue of Lung Cancer Worldwide: ow.ly/91j150SFsUC #LCSM

This study aimed to evaluate the clinical value of a tumor-naïve, methylation-based cell-free DNA assay in a large cohort of patients with resected #NSCLC. Read more about the findings here: ow.ly/Qe4T50SFsZ6 #LCSM

These authors/members of the Staging & Prognostic Factors Committee of the Advisory Boards & Participating Institutions present their proposal for the revision of the TNM stage groupings in the 9th edition of the TNM Classification for Pleural Mesothelioma:bit.ly/4d4rq0t

There is limited literature on the prevalence of EGFR mutations in early-stage NSCLC. EARLY-EGFR (NCT04742192), a cross-sectional multi-region study, determined the prevalence of EGFR mutations in early-stage NSCLC. Read about the results here: bit.ly/3W9nmFx #LCSM

The IASLC collected/analyzed a new database of pts w/#lungcancer to inform the forthcoming 9th edition of the classification of LC based on its anatomic extent (TNM), which is periodically revised. The results concerning the LC stage groups are here: bit.ly/3We2tJe #LCSM

The R-classification for the 9th Ed. of stage classification of LC is proposed to retain the same overall framework/descriptors as the 8th, w/more precise definitions of descriptors. These refinements should facilitate application & further research. bit.ly/441RqX1 #LCSM

A study focused on whether STAS could be a useful add'l histologic descriptor to supplement existing ones of VPI & LVI. The data supports the recommendation to include STAS as histologic descriptor for the 9th Ed. of the TNM Classification of #lungcancer.bit.ly/3IZkx3x

A phase 3 RATIONALE-312 study aimed to evaluate the efficacy & safety of tislelizumab + chemotherapy as first-line treatment for ES-SCLC, which exhibited statistically significant clinical benefit & manageable safety compared w/placebo + chemotherapy.bit.ly/4akAXPN #LCSM

To help members navigate the current treatment options available for pts with resectable LC, the IASLC convened a global multidisciplinary expert panel to review data and provide guidelines/flow charts to select the optimal regimen for their patient. bit.ly/3LwKQiW #LCSM

Analyzing pts w/unresectable locally advanced #NSCLC on a phase 2 trial of short course consolidation immunotherapy after CRT, the authors found that ctDNA MRD is highly prognostic & might enable personalizing the duration of treatment. bit.ly/3A80Q8t #LCSM Max Diehn, MD/PhD

In this analysis, aimed to determine whether longitudinal EGFR-mutation ctDNA testing could detect PD before radiologic detection, the authors concluded that longitudinal ctDNA monitoring may detect PD before radiologic PD. Learn More: bit.ly/46rjhRZ #LCSM

High-quality #LungCancer screening has a favorable net-benefit in early detection, thus better outcomes. But screening low-risk individuals like those with neither family histories, nor smoking histories may not have a benefit at all. Read More: bit.ly/LDCTScreening #LCSM

This month, learn about #lungcancer screening, treatment & tobacco cessation efforts in one of the Baltic states. Access Estonia's contribution to the Lung Cancer Worldwide series here! bit.ly/3yAhehL #LCSM

This study aimed to validate the discriminatory ability and clinical utility of the N descriptor of the newly proposed 9th edition of the TNM staging system for #LungCancer in a large independent cohort. Click here for the details: bit.ly/3Ze4FUv #LCSM

Novel immune checkpoints are constantly emerging to treat EGFR-mutant #NSCLC. Combination therapy incorporating CD47 blockade holds substantial promise for clinical translation in developing more effective therapeutic approaches against EGFR-mutant NSCLC. bit.ly/3XfAQRZ

We are thrilled to have 20 participants join the faculty at the 2024 IASLC Reviewer Workshop, organized by IASLC, JTO and JTO CRR on Sep 11 in San Diego. We look forward to many engaging discussions and learning! JTO & JTO CRR #WCLC24 #reviewer

The authors report long-term outcomes from a pooled analysis of pts with previously untreated metastatic NSCLC with PD-L1 TPS less than 1% enrolled in phase III studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy. bit.ly/3KgCsmY #LCSM

#WCLC24 Meet the Editors: Come and have a chat with JTO Editor-in-Chief Alex A. Adjei and JTO CRR Editor-in-Chief Dr. Emily Stone. Join us in Room 26B at 2-3 PM today! JTO & JTO CRR